Malignant ovarian germ cell tumor (MOGCT), a rare form of ovarian malignancy, predominantly affects adolescents and young women of reproductive age [1, 2]. This group of ovarian cancers includes various subtypes, including dysgerminoma, yolk sac tumors, embryonal carcinoma, non-gestational choriocarcinoma, mixed germ cell tumors, and immature teratomas, each with distinct characteristics [3-5]. Dysgerminoma, akin to male seminoma, represents the most prevalent histological variant and immature teratoma and is associated with relatively high bilaterality rates [4, 6, 7].

Platinum-based chemotherapy regimens have proven effective in extending survival and preserving fertility [1, 8]. Given the chemosensitivity of these tumor cells, fertility-sparing surgery (FSS) has become a preferred treatment approach, particularly in patients desiring to preserve their reproductive capability. FSS, which involves complete staging and the preservation of at least the uterine corpus and a portion of one ovary, has emerged as the primary treatment modality in patients with early-stage MOGCT [8-10]. However, a couple of studies in which the potential risks of FSS use have been extensively discussed have stated that FSS use can be justifiable in advanced-stage MOGCT patients [10, 11].

Menstrual and reproductive outcomes in patients who survived MOGCT are reportedly similar to those of age-matched healthy women [1, 12]. Ovarian function is typically restored following three or four cycles of platinum-based therapy [12]. However, fertility rates vary significantly, including among patients with advanced MOGCT [2, 8, 11].

In this context, in this case study, an advanced MOGCT patient who underwent complete staging and was treated with FSS coupled with adjuvant cisplatin-based chemotherapy and still achieved spontaneous pregnancy is presented.